$LAB
STANDARD BIOTOOLS INC. Stock $lab

$lab Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000116219421000087 Filed on November 09, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2021 Q2
Revenue	$38.27M	$28.50M	$31.02M
YoY Change	-14.22%	-28.49%	19.03%
Cost Of Revenue	$18.02M	$14.84M	$14.60M
YoY Change	-2.0%	2.03%	36.17%
Gross Profit	$20.24M	$13.67M	$16.42M
YoY Change	-8.32%	-34.28%	38.87%
Gross Profit Margin	52.9%	47.95%	52.94%
Selling, General & Admin	$22.96M	$24.07M	$24.25M
YoY Change	-28.1%	6.25%	17.62%
% of Gross Profit	113.43%	176.11%	147.66%
Research & Development	$8.541M	$9.209M	$9.441M
YoY Change	-23.67%	13.3%	11.75%
% of Gross Profit	42.19%	67.37%	57.49%
Depreciation & Amortization	$3.883M	$3.872M	$3.899M
YoY Change	-75.62%	-2.22%	-0.03%
% of Gross Profit	19.18%	28.33%	23.74%
Operating Expenses	$31.50M	$48.12M	$48.29M
YoY Change	-26.95%	6.16%	21.37%
Operating Profit	-$11.26M	-$19.61M	-$17.27M
YoY Change	-46.49%	258.93%	25.81%
Interest Expense	-$1.072M	$968.0K	$896.0K
YoY Change	20.45%	9.38%	-0.11%
% of Operating Profit
Other Income/Expense, Net	$2.097M	$315.0K	$504.0K
YoY Change	177.75%	194.39%	8.86%
Pretax Income	-$10.24M	-$15.27M	-$17.66M
YoY Change	-39.88%	144.55%	24.72%
Income Tax	-$814.0K	-$1.400M	-$500.0K
% Of Pretax Income
Net Earnings	-$9.429M	-$13.84M	-$17.14M
YoY Change	-47.69%	130.76%	31.72%
Net Earnings / Revenue	-24.64%	-48.57%	-55.27%
Basic Earnings Per Share		-$0.18	-$0.23
Diluted Earnings Per Share	-$123.0K	-$0.18	-$0.23
COMMON SHARES
Basic Shares Outstanding	76.49M shares	76.30M shares	75.45M shares
Diluted Shares Outstanding		76.30M shares	75.45M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$28.45M	$29.31M	$30.86M
YoY Change	-58.48%	-59.46%	-32.02%
Cash & Equivalents	$28.45M	$29.31M	$30.86M
Short-Term Investments	$0.00
Other Short-Term Assets	$4.470M	$5.926M	$6.603M
YoY Change	10.89%	3.96%	57.21%
Inventory	$20.83M	$24.50M	$25.07M
Prepaid Expenses
Receivables	$18.32M	$13.73M	$15.67M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$72.07M	$73.47M	$78.21M
YoY Change	-38.75%	-40.11%	-0.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$28.03M	$28.91M	$27.72M
YoY Change	59.91%	283.92%	252.42%
Goodwill	$106.4M	$106.4M	$106.5M
YoY Change	-0.17%	-0.03%	0.15%
Intangibles	$27.93M	$30.99M	$34.08M
YoY Change	-30.54%	-27.85%	-25.33%
Long-Term Investments
YoY Change
Other Assets	$3.689M	$4.692M	$4.106M
YoY Change	-21.18%	-4.32%	-18.43%
Total Long-Term Assets	$203.1M	$208.7M	$211.1M
YoY Change	-1.91%	4.2%	3.54%
TOTAL ASSETS
Total Short-Term Assets	$72.07M	$73.47M	$78.21M
Total Long-Term Assets	$203.1M	$208.7M	$211.1M
Total Assets	$275.2M	$282.2M	$289.3M
YoY Change	-15.26%	-12.63%	2.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.60M	$10.79M	$11.22M
YoY Change	14.99%	-1.69%	19.61%
Accrued Expenses	$8.673M	$8.188M	$8.682M
YoY Change	-27.01%	24.72%	50.78%
Deferred Revenue	$11.95M	$12.86M	$13.98M
YoY Change	-11.34%	-4.3%	-2.13%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$6.838M
YoY Change
Total Short-Term Liabilities	$49.57M	$47.29M	$52.85M
YoY Change	-8.63%	10.51%	37.81%
LONG-TERM LIABILITIES
Long-Term Debt	$64.21M	$64.04M	$53.94M
YoY Change	18.41%	18.38%	-0.11%
Other Long-Term Liabilities	$882.0K	$954.0K	$276.0K
YoY Change	-33.83%	77.99%	-48.7%
Total Long-Term Liabilities	$882.0K	$954.0K	$276.0K
YoY Change	-33.83%	77.99%	-48.7%
TOTAL LIABILITIES
Total Short-Term Liabilities	$49.57M	$47.29M	$52.85M
Total Long-Term Liabilities	$882.0K	$954.0K	$276.0K
Total Liabilities	$180.6M	$182.9M	$179.9M
YoY Change	-2.74%	6.93%	20.21%
SHAREHOLDERS EQUITY
Retained Earnings	-$736.0M	-$726.6M	-$712.7M
YoY Change	8.75%	10.3%	9.19%
Common Stock	$77.00K	$76.00K	$76.00K
YoY Change	2.67%	2.7%	7.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$94.60M	$99.34M	$109.5M
YoY Change
Total Liabilities & Shareholders Equity	$275.2M	$282.2M	$289.3M
YoY Change	-15.26%	-12.63%	2.47%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2021 Q2
OPERATING ACTIVITIES
Net Income	-$9.429M	-$13.84M	-$17.14M
YoY Change	-47.69%	130.76%	31.72%
Depreciation, Depletion And Amortization	$3.883M	$3.872M	$3.899M
YoY Change	-75.62%	-2.22%	-0.03%
Cash From Operating Activities	-$7.002M	-$9.494M	-$14.66M
YoY Change	-54.58%	106.84%	425.59%
INVESTING ACTIVITIES
Capital Expenditures	-$463.0K	-$1.706M	-$4.172M
YoY Change	-96.36%	-601.76%	-751.88%
Acquisitions
YoY Change
Other Investing Activities	-$682.0K	$0.00	$0.00
YoY Change	-101.29%	-100.0%	-100.0%
Cash From Investing Activities	-$1.145M	-$1.706M	-$4.172M
YoY Change	-102.86%	-112.91%	-141.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	7.297M	9.821M	-133.0K
YoY Change	-65.01%	-51.9%	-126.08%
NET CHANGE
Cash From Operating Activities	-7.002M	-9.494M	-14.66M
Cash From Investing Activities	-1.145M	-1.706M	-4.172M
Cash From Financing Activities	7.297M	9.821M	-133.0K
Net Change In Cash	-850.0K	-1.379M	-18.97M
YoY Change	-101.87%	-104.75%	-341.64%
FREE CASH FLOW
Cash From Operating Activities	-$7.002M	-$9.494M	-$14.66M
Capital Expenditures	-$463.0K	-$1.706M	-$4.172M
Free Cash Flow	-$6.539M	-$7.788M	-$10.49M
YoY Change	142.19%	57.97%	205.89%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001162194
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member
CY2021Q3	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P3M
CY2021Q3	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2021Q3	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2021Q3	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-34180
	dei	Entity Registrant Name EntityRegistrantName	FLUIDIGM CORP
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0513190
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2 Tower Place, Ste 2000
	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco,
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
	dei	City Area Code CityAreaCode	650
	dei	Local Phone Number LocalPhoneNumber	266-6000
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
	dei	Trading Symbol TradingSymbol	FLDM
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	76485632	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29309000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	68520000	USD
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	356000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	356000	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	13732000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	25423000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	24498000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	19689000	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5926000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4031000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	73465000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	117663000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28913000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17531000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	37698000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	38114000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4692000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4680000	USD
CY2021Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	30992000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	40206000	USD
CY2021Q3	us-gaap	Goodwill Goodwill	106428000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	106563000	USD
CY2021Q3	us-gaap	Assets Assets	282188000	USD
CY2020Q4	us-gaap	Assets Assets	324757000	USD
CY2021Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	54051000	USD
CY2020Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	54224000	USD
CY2021Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	7229000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	10786000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9220000	USD
CY2021Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8286000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	13787000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2873000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2973000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8188000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11882000	USD
CY2021Q3	fldm	Deferred Grant Revenue Current DeferredGrantRevenueCurrent	4299000	USD
CY2020Q4	fldm	Deferred Grant Revenue Current DeferredGrantRevenueCurrent	2912000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	12858000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	13475000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	47290000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	54249000	USD
CY2021Q3	us-gaap	Secured Debt SecuredDebt	9993000	USD
CY2020Q4	us-gaap	Secured Debt SecuredDebt	0	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	8697000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	38170000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	38178000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	6034000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	7990000	USD
CY2021Q3	fldm	Deferred Grant Revenue Noncurrent DeferredGrantRevenueNoncurrent	19130000	USD
CY2020Q4	fldm	Deferred Grant Revenue Noncurrent DeferredGrantRevenueNoncurrent	21036000	USD
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	954000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1333000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	182851000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	185707000	USD
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	76485000	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	76485000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74543000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74543000	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	76000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	75000	USD
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	826559000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	815624000	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-730000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	112000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-726568000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-676761000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	99337000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	139050000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	282188000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	324757000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	28504000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	39861000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	92316000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	93536000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9209000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8128000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29403000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25275000	USD
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	24072000	USD
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22655000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	75928000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	65966000	USD
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	48116000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	45325000	USD
	us-gaap	Operating Expenses OperatingExpenses	148516000	USD
	us-gaap	Operating Expenses OperatingExpenses	127668000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-19612000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5464000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-56200000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-34132000	USD
CY2021Q3	us-gaap	Interest Expense InterestExpense	968000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	885000	USD
	us-gaap	Interest Expense InterestExpense	2751000	USD
	us-gaap	Interest Expense InterestExpense	2682000	USD
CY2021Q3	fldm	Research And Development Arrangement Contract To Perform For Others Other Income Recognized ResearchAndDevelopmentArrangementContractToPerformForOthersOtherIncomeRecognized	5000000	USD
CY2020Q3	fldm	Research And Development Arrangement Contract To Perform For Others Other Income Recognized ResearchAndDevelopmentArrangementContractToPerformForOthersOtherIncomeRecognized	0	USD
	fldm	Research And Development Arrangement Contract To Perform For Others Other Income Recognized ResearchAndDevelopmentArrangementContractToPerformForOthersOtherIncomeRecognized	5000000	USD
	fldm	Research And Development Arrangement Contract To Perform For Others Other Income Recognized ResearchAndDevelopmentArrangementContractToPerformForOthersOtherIncomeRecognized	0	USD
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	315000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	107000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	534000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-248000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15265000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6242000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-53417000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37062000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1422000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-243000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3609000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2068000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-13843000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-5999000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-49808000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-34994000	USD
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.66
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.66
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.49
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.49
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	76301000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	76301000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	72486000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72486000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75494000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	75494000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	71294000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	71294000	shares
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-13843000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-5999000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-49808000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-34994000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-34994000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-446000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	523000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-842000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	329000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2020Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-3000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-36000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-446000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	520000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-842000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	293000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14289000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5479000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-50650000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-34701000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	139050000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-525000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3677000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-18821000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-443000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	122938000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-1027000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	685000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	209000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3741000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-17143000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	47000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	109450000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-143000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	-1000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4320000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-13843000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-446000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	99337000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	153612000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-146000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2364000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	2049000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-15980000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-303000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	141496000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-116000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	645000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3633000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-13015000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	76000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	132719000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-123000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	450000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	20228000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	180000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4358000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-5999000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	520000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	151973000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-49808000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-34994000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	11738000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	10358000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8944000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8929000	USD
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	2744000	USD
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	2988000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	427000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	415000	USD
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	380000	USD
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1863000	USD
	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	1539000	USD
	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	680000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-6000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-191000	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	11000	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	13000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-11438000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-967000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7467000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6773000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2720000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2395000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1412000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4996000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2290000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	1258000	USD
	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	-5394000	USD
	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	3995000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-8019000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-4175000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37059000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11684000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	5154000	USD
	fldm	Proceeds From Research And Development Grant ProceedsFromResearchAndDevelopmentGrant	2000000	USD
	fldm	Proceeds From Research And Development Grant ProceedsFromResearchAndDevelopmentGrant	11151000	USD
	us-gaap	Proceeds From Sale Of Other Investments ProceedsFromSaleOfOtherInvestments	0	USD
	us-gaap	Proceeds From Sale Of Other Investments ProceedsFromSaleOfOtherInvestments	5010000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Other Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments	0	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Other Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments	31800000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	12801000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2010000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10801000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	40797000	USD
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	10000000	USD
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	20226000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	501000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	208000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	450000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	685000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	645000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1695000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	387000	USD
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	35000	USD
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	509000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8662000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20425000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-13000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	86000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-39211000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	49624000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69536000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23736000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30325000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	73360000	USD
	us-gaap	Interest Paid Net InterestPaidNet	1565000	USD
	us-gaap	Interest Paid Net InterestPaidNet	86000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1113000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	386000	USD
	fldm	Non Cash Right Of Use Assets And Lease Liabilities NonCashRightOfUseAssetsAndLeaseLiabilities	2241000	USD
	fldm	Non Cash Right Of Use Assets And Lease Liabilities NonCashRightOfUseAssetsAndLeaseLiabilities	35950000	USD
	fldm	Asset Retirement Obligations Incurred But Not Yet Paid AssetRetirementObligationsIncurredButNotYetPaid	702000	USD
	fldm	Asset Retirement Obligations Incurred But Not Yet Paid AssetRetirementObligationsIncurredButNotYetPaid	319000	USD
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	Certain prior period amounts in the condensed consolidated financial statements were reclassified to conform with the current period presentation. These reclassifications were immaterial and did not affect prior period total assets, total liabilities, stockholders’ equity, total revenue, total costs and expenses, loss from operations or net loss.
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions believed to be reasonable, which together form the basis for making judgments about the carrying values of assets and liabilities. The full extent to which the COVID-19 pandemic impacts our business, results of operations and financial condition will depend on numerous evolving factors including, but not limited to, the magnitude and duration of the pandemic, the extent to which it will impact worldwide macroeconomic conditions, including the speed of recovery, and governmental and business reactions to the pandemic. We assessed certain accounting matters that generally require consideration of forecasted financial information, including the unknown impact of COVID-19 as of September 30, 2021. These accounting matters included, but were not limited to, our allowance for doubtful accounts and credit losses, inventory and related reserves and the carrying value of goodwill and other long-lived assets.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual results could differ materially from these estimates and could have a material adverse effect on our condensed consolidated financial statements.</span></div>
CY2020Q1	us-gaap	Legal Fees LegalFees	400000	USD
	fldm	Product Warranty Term ProductWarrantyTerm	P1Y
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Business and Credit Risk</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to credit risk consist of cash, cash equivalents, investments, and accounts receivable. Our cash, cash equivalents, and investments may consist of deposits held with banks, money market funds, and other highly liquid investments that may at times exceed federally insured limits. Cash equivalents and investments are financial instruments that potentially subject us to concentrations of risk. Under our investment policy, we invest primarily in securities issued by the U.S. government. The goals of our investment policy, in order of priority, are as follows: preserve capital, meet liquidity needs, and optimize returns. </span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally do not require collateral to support credit sales. To reduce credit risk, we perform credit evaluations of our customers. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No customer represented more than 10% of total revenue for either the three or nine months ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One customer from whom we derived product and development revenue exceed</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ed 10% of total revenue for both the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and nine months ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> September 30, 2020. </span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One customer had an outstanding trade receivable balance that represented more than 10% of total billed receivables as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. No customer had an outstanding trade receivable balance that represented more than 10% of total billed receivables as of December 31, 2020.</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products include components that are currently procured from a single source or a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> limited number of sources. We believe that other vendors would be able to provide similar components; however, the qualification of such vendors may require </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">start-up ti</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">me. In order to mitigate any adverse impacts from a disruption of supply, we attempt to maintain an adequate supply of critical limited-source components.</span>
CY2020Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020Q3	fldm	Research And Development Arrangement Contract To Perform For Others Maximum Contract Value ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumContractValue	34000000	USD
CY2021Q3	us-gaap	Secured Debt SecuredDebt	10000000	USD
CY2021Q3	fldm	Debt Instrument Periodic Payment Number Of Installments DebtInstrumentPeriodicPaymentNumberOfInstallments	24	monthly_installment
CY2021Q3	fldm	Debt Instrument Incremental Payment Percent DebtInstrumentIncrementalPaymentPercent	0.065
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	27945000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	27463000	shares
CY2021Q3	fldm	Collaborative Arrangements Annual Payments Receivable Under Development Agreement CollaborativeArrangementsAnnualPaymentsReceivableUnderDevelopmentAgreement	400000	USD
CY2020Q4	fldm	Research And Development Arrangement Contract To Perform For Others Maximum Contract Value ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumContractValue	34000000	USD
	fldm	Research And Development Arrangement Contract To Perform For Others Liquidated Damages Percentage ResearchAndDevelopmentArrangementContractToPerformForOthersLiquidatedDamagesPercentage	0.33
	fldm	Research And Development Arrangement Contract To Perform For Others Liquidated Damages Term ResearchAndDevelopmentArrangementContractToPerformForOthersLiquidatedDamagesTerm	P6M
CY2021Q3	fldm	Research And Development Arrangement Contract To Perform For Others Amount ResearchAndDevelopmentArrangementContractToPerformForOthersAmount	32236000	USD
CY2020Q4	fldm	Research And Development Arrangement Contract To Perform For Others Amount ResearchAndDevelopmentArrangementContractToPerformForOthersAmount	25436000	USD
CY2021Q3	fldm	Research And Development Arrangement Contract To Perform For Others Expenses ResearchAndDevelopmentArrangementContractToPerformForOthersExpenses	3807000	USD
CY2020Q4	fldm	Research And Development Arrangement Contract To Perform For Others Expenses ResearchAndDevelopmentArrangementContractToPerformForOthersExpenses	1488000	USD
CY2021Q3	fldm	Research And Development Arrangement Contract To Perform For Others Other Income ResearchAndDevelopmentArrangementContractToPerformForOthersOtherIncome	5000000	USD
CY2020Q4	fldm	Research And Development Arrangement Contract To Perform For Others Other Income ResearchAndDevelopmentArrangementContractToPerformForOthersOtherIncome	0	USD
CY2021Q3	fldm	Deferred Grant Revenue DeferredGrantRevenue	23429000	USD
CY2020Q4	fldm	Deferred Grant Revenue DeferredGrantRevenue	23948000	USD
CY2021Q3	fldm	Deferred Grant Income Current DeferredGrantIncomeCurrent	4299000	USD
CY2020Q4	fldm	Deferred Grant Income Current DeferredGrantIncomeCurrent	2912000	USD
CY2021Q3	fldm	Deferred Grant Income Noncurrent DeferredGrantIncomeNoncurrent	19130000	USD
CY2020Q4	fldm	Deferred Grant Income Noncurrent DeferredGrantIncomeNoncurrent	21036000	USD
CY2021Q3	fldm	Deferred Grant Revenue DeferredGrantRevenue	23429000	USD
CY2020Q4	fldm	Deferred Grant Revenue DeferredGrantRevenue	23948000	USD
CY2021Q3	fldm	Research And Development Arrangement Contract To Perform For Others Amount ResearchAndDevelopmentArrangementContractToPerformForOthersAmount	32236000	USD
CY2020Q4	fldm	Research And Development Arrangement Contract To Perform For Others Amount ResearchAndDevelopmentArrangementContractToPerformForOthersAmount	25436000	USD
CY2021Q3	fldm	Research And Development Arrangement Contract To Perform For Others Funding Received ResearchAndDevelopmentArrangementContractToPerformForOthersFundingReceived	31736000	USD
CY2020Q4	fldm	Research And Development Arrangement Contract To Perform For Others Funding Received ResearchAndDevelopmentArrangementContractToPerformForOthersFundingReceived	25436000	USD
CY2021Q3	fldm	Research And Development Arrangement Receivables ResearchAndDevelopmentArrangementReceivables	500000	USD
CY2020Q4	fldm	Research And Development Arrangement Receivables ResearchAndDevelopmentArrangementReceivables	0	USD
	fldm	Research And Development Arrangement Contract To Perform For Others Capital Expenditures To Be Incurred ResearchAndDevelopmentArrangementContractToPerformForOthersCapitalExpendituresToBeIncurred	23000000	USD
	fldm	Research And Development Arrangement Contract To Perform For Others Capital Expenditures ResearchAndDevelopmentArrangementContractToPerformForOthersCapitalExpenditures	21600000	USD
CY2021Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	10817000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	28504000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	39861000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	92316000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	93536000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	28504000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	39861000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	92316000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	93536000	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	21500000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	9700000	USD
	fldm	Contract With Customer Liability Increase From Cash Receipts ContractWithCustomerLiabilityIncreaseFromCashReceipts	7100000	USD
CY2021Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	18900000	USD
CY2021Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	5923000	USD
CY2021Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	3707000	USD
CY2021Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	4473000	USD
CY2021Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	24920000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	3146000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	12581000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	12475000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2110000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	702000	USD
CY2021Q3	fldm	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	1405000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	32419000	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29309000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	68520000	USD
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1016000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1016000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30325000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69536000	USD
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	16000	USD
CY2021Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	16000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1000000	USD
CY2021Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1000000	USD
CY2021Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	11511000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28913000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17531000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	8292000	USD
CY2021Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	867000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1214000	USD
CY2021Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	12120000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	10183000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	24498000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	19689000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	32586000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	31544000	USD
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	25673000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	23989000	USD
CY2021Q3	us-gaap	Construction In Progress Gross ConstructionInProgressGross	22000000	USD
CY2020Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	9976000	USD
CY2021Q3	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	2365000	USD
CY2020Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	7842000	USD
CY2021Q3	us-gaap	Accrued Vacation Current AccruedVacationCurrent	3730000	USD
CY2020Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	3367000	USD
CY2021Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	2191000	USD
CY2020Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	2578000	USD
CY2021Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8286000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	13787000	USD
CY2020Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	1663000	USD
CY2019Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	1390000	USD
	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	554000	USD
	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	677000	USD
	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	713000	USD
	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	387000	USD
CY2021Q3	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	1504000	USD
CY2020Q3	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	1680000	USD
CY2021Q3	fldm	Debt Instrument Covenant Convertible Debt Threshold DebtInstrumentCovenantConvertibleDebtThreshold	600000	USD
CY2021Q3	fldm	Debt Instrument Incremental Payment Percent DebtInstrumentIncrementalPaymentPercent	0.065
CY2021Q3	fldm	Debt Instrument Periodic Payment Number Of Installments DebtInstrumentPeriodicPaymentNumberOfInstallments	24	monthly_installment
CY2021Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2021Q3	fldm	Operating Lease Right Of Use Asset Gross OperatingLeaseRightOfUseAssetGross	43972000	USD
CY2020Q4	fldm	Operating Lease Right Of Use Asset Gross OperatingLeaseRightOfUseAssetGross	41900000	USD
CY2021Q3	fldm	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	6274000	USD
CY2020Q4	fldm	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	3786000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	37698000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	38114000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2873000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2973000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	38170000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	38178000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	41043000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	41151000	USD
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y7M6D
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.120
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.119
CY2021Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	6332000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1635000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.33
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y2M12D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	93000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.56
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	37000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.71
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	22000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	81000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	10.06
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1610000	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.13
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y9M18D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1473000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	1459000	shares
CY2021Q3	fldm	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice	7.23
	fldm	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term One ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTermOne	P5Y7M6D
CY2021Q3	fldm	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAggregateIntrinsicValue	1374000	USD
	fldm	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber	151000	shares
CY2021Q3	fldm	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice	6.19
	fldm	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Remaining Contractual Term1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageRemainingContractualTerm1	P8Y1M6D
CY2021Q3	fldm	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue	99000	USD
CY2021Q3	us-gaap	Share Price SharePrice	6.59
	fldm	Employee Stock Purchase Plan Offering Period EmployeeStockPurchasePlanOfferingPeriod	P6M
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.85
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4320000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4357000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11738000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10358000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1400000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-200000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3600000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2100000	USD
CY2021Q3	us-gaap	Decrease In Unrecognized Tax Benefits Is Reasonably Possible DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible	800000	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment

Files In Submission

Name	View Source	Status
0001162194-21-000087-index-headers.html	Edgar Link	pending
0001162194-21-000087-index.html	Edgar Link	pending
0001162194-21-000087.txt	Edgar Link	pending
0001162194-21-000087-xbrl.zip	Edgar Link	pending
exhibit1013q2021radxamend4.htm	Edgar Link	pending
exhibit31110q3q2021.htm	Edgar Link	pending
exhibit31210q3q2021.htm	Edgar Link	pending
exhibit32110q3q2021.htm	Edgar Link	pending
exhibit32210q3q2021.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
fldm-20210930.htm	Edgar Link	pending
fldm-20210930.xsd	Edgar Link	pending
fldm-20210930_cal.xml	Edgar Link	unprocessable
fldm-20210930_def.xml	Edgar Link	unprocessable
fldm-20210930_g1.jpg	Edgar Link	pending
fldm-20210930_htm.xml	Edgar Link	completed
fldm-20210930_lab.xml	Edgar Link	unprocessable
fldm-20210930_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LAB
STANDARD BIOTOOLS INC. Stock $lab

2021 Q4 Form 10-Q Financial Statement

#000116219421000087 Filed on November 09, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LAB STANDARD BIOTOOLS INC. Stock $lab

2021 Q4 Form 10-Q Financial Statement

#000116219421000087 Filed on November 09, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LAB
STANDARD BIOTOOLS INC. Stock $lab